The effects of a treatment combination of anti-VEGF injections, laser coagulation and cryotherapy on patients with type 3 Coat’s disease

Abstract Background To examined the curative effect of vitreous injection with ranibizumab,laser coagulation and cryotherapy in treating stage 3 Coats’ disease with exudative retinal detachment. Methods Seventeen patients with stage 3 Coats’ disease were enrolled in the study. All eyes were treated...

Full description

Bibliographic Details
Main Authors: Songfeng Li, Guangda Deng, Jinghua Liu, Yan Ma, Hai Lu
Format: Article
Language:English
Published: BMC 2017-05-01
Series:BMC Ophthalmology
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12886-017-0469-4
id doaj-b784be0a1b5e419ea6146bc3e9feb3dc
record_format Article
spelling doaj-b784be0a1b5e419ea6146bc3e9feb3dc2020-11-25T00:30:20ZengBMCBMC Ophthalmology1471-24152017-05-011711710.1186/s12886-017-0469-4The effects of a treatment combination of anti-VEGF injections, laser coagulation and cryotherapy on patients with type 3 Coat’s diseaseSongfeng Li0Guangda Deng1Jinghua Liu2Yan Ma3Hai Lu4Beijing Ophthalmology and Visual Science Key Laboratory, Beijing Tongren Eye Center, Beijing Tongren Hospital,Capital Medical UniversityBeijing Ophthalmology and Visual Science Key Laboratory, Beijing Tongren Eye Center, Beijing Tongren Hospital,Capital Medical UniversityBeijing Ophthalmology and Visual Science Key Laboratory, Beijing Tongren Eye Center, Beijing Tongren Hospital,Capital Medical UniversityBeijing Ophthalmology and Visual Science Key Laboratory, Beijing Tongren Eye Center, Beijing Tongren Hospital,Capital Medical UniversityBeijing Ophthalmology and Visual Science Key Laboratory, Beijing Tongren Eye Center, Beijing Tongren Hospital,Capital Medical UniversityAbstract Background To examined the curative effect of vitreous injection with ranibizumab,laser coagulation and cryotherapy in treating stage 3 Coats’ disease with exudative retinal detachment. Methods Seventeen patients with stage 3 Coats’ disease were enrolled in the study. All eyes were treated with vitreous injection of ranibizumab as initial treatment, and subsequent treatment depended on the absorption of subretinal fluid, Including cryotherapy and laser photocoagulation. Repeat treatment for the two treatment intervals occurred in ≥1 month. The mean follow-up time was 24.12 ± 5.99 months. The main data evaluation and outcome measurements included the patient’s vision, intraocular pressure(IOP), optical coherence tomography (OCT), slit lamp examination, indirect ophthalmoscopy, color Doppler imaging (CDI) and color fundus image analysis. The following variables were compared between groups: abnormal vascular changes, subretinal fluid and exudate absorption, retinal reattachment and complications. The final follow-up results were used to determine the effectiveness of treatment. Results Of the 17 patients included, 88.24% were male and 11.76% were female. Visual acuity was less than 0.02 in 12 eyes before surgery and 8 eyes after surgery. Visual acuity improved in 7 eyes, accounting for 41.18% of cases, and remained unchanged in 7 eyes, accounting for 41.18% of cases. Three patients were too young to undergo the operation, accounting for 17.65% of cases. The best vision was 0.1. Patients were treated 1 to 5 times for an average of 2.82 ± 0.95 times each. There was no statistically significant difference (t = 1.580, p = 0.135) between the preoperative and postoperative intraocular pressures. However, there was a statistically significant difference between the preoperative and postoperative retinal detachment height (2- related samples Wilcoxon signed rank test with z = 3.517, p = 0.000). The results further showed that all patients had different degrees of subretinal fluid absorption, and some of the new blood vessels subsided. All patients were successfully treated with laser and cryosurgery. No ocular or systemic complications were observed during follow-up. Conclusions Intravitreal ranibizumab (IVR), laser coagulation and cryotherapy were effective in the treatment of Coats’ disease with exudative retinal detachment. Trial registration number We retrospectively registered our study, The trial registration number (TRN) is ChiCTR-ONC-17011161 and date of registration is April 16, 2017.http://link.springer.com/article/10.1186/s12886-017-0469-4Coats’diseaseTreatmentRetinal detachmentRanibizumab
collection DOAJ
language English
format Article
sources DOAJ
author Songfeng Li
Guangda Deng
Jinghua Liu
Yan Ma
Hai Lu
spellingShingle Songfeng Li
Guangda Deng
Jinghua Liu
Yan Ma
Hai Lu
The effects of a treatment combination of anti-VEGF injections, laser coagulation and cryotherapy on patients with type 3 Coat’s disease
BMC Ophthalmology
Coats’disease
Treatment
Retinal detachment
Ranibizumab
author_facet Songfeng Li
Guangda Deng
Jinghua Liu
Yan Ma
Hai Lu
author_sort Songfeng Li
title The effects of a treatment combination of anti-VEGF injections, laser coagulation and cryotherapy on patients with type 3 Coat’s disease
title_short The effects of a treatment combination of anti-VEGF injections, laser coagulation and cryotherapy on patients with type 3 Coat’s disease
title_full The effects of a treatment combination of anti-VEGF injections, laser coagulation and cryotherapy on patients with type 3 Coat’s disease
title_fullStr The effects of a treatment combination of anti-VEGF injections, laser coagulation and cryotherapy on patients with type 3 Coat’s disease
title_full_unstemmed The effects of a treatment combination of anti-VEGF injections, laser coagulation and cryotherapy on patients with type 3 Coat’s disease
title_sort effects of a treatment combination of anti-vegf injections, laser coagulation and cryotherapy on patients with type 3 coat’s disease
publisher BMC
series BMC Ophthalmology
issn 1471-2415
publishDate 2017-05-01
description Abstract Background To examined the curative effect of vitreous injection with ranibizumab,laser coagulation and cryotherapy in treating stage 3 Coats’ disease with exudative retinal detachment. Methods Seventeen patients with stage 3 Coats’ disease were enrolled in the study. All eyes were treated with vitreous injection of ranibizumab as initial treatment, and subsequent treatment depended on the absorption of subretinal fluid, Including cryotherapy and laser photocoagulation. Repeat treatment for the two treatment intervals occurred in ≥1 month. The mean follow-up time was 24.12 ± 5.99 months. The main data evaluation and outcome measurements included the patient’s vision, intraocular pressure(IOP), optical coherence tomography (OCT), slit lamp examination, indirect ophthalmoscopy, color Doppler imaging (CDI) and color fundus image analysis. The following variables were compared between groups: abnormal vascular changes, subretinal fluid and exudate absorption, retinal reattachment and complications. The final follow-up results were used to determine the effectiveness of treatment. Results Of the 17 patients included, 88.24% were male and 11.76% were female. Visual acuity was less than 0.02 in 12 eyes before surgery and 8 eyes after surgery. Visual acuity improved in 7 eyes, accounting for 41.18% of cases, and remained unchanged in 7 eyes, accounting for 41.18% of cases. Three patients were too young to undergo the operation, accounting for 17.65% of cases. The best vision was 0.1. Patients were treated 1 to 5 times for an average of 2.82 ± 0.95 times each. There was no statistically significant difference (t = 1.580, p = 0.135) between the preoperative and postoperative intraocular pressures. However, there was a statistically significant difference between the preoperative and postoperative retinal detachment height (2- related samples Wilcoxon signed rank test with z = 3.517, p = 0.000). The results further showed that all patients had different degrees of subretinal fluid absorption, and some of the new blood vessels subsided. All patients were successfully treated with laser and cryosurgery. No ocular or systemic complications were observed during follow-up. Conclusions Intravitreal ranibizumab (IVR), laser coagulation and cryotherapy were effective in the treatment of Coats’ disease with exudative retinal detachment. Trial registration number We retrospectively registered our study, The trial registration number (TRN) is ChiCTR-ONC-17011161 and date of registration is April 16, 2017.
topic Coats’disease
Treatment
Retinal detachment
Ranibizumab
url http://link.springer.com/article/10.1186/s12886-017-0469-4
work_keys_str_mv AT songfengli theeffectsofatreatmentcombinationofantivegfinjectionslasercoagulationandcryotherapyonpatientswithtype3coatsdisease
AT guangdadeng theeffectsofatreatmentcombinationofantivegfinjectionslasercoagulationandcryotherapyonpatientswithtype3coatsdisease
AT jinghualiu theeffectsofatreatmentcombinationofantivegfinjectionslasercoagulationandcryotherapyonpatientswithtype3coatsdisease
AT yanma theeffectsofatreatmentcombinationofantivegfinjectionslasercoagulationandcryotherapyonpatientswithtype3coatsdisease
AT hailu theeffectsofatreatmentcombinationofantivegfinjectionslasercoagulationandcryotherapyonpatientswithtype3coatsdisease
AT songfengli effectsofatreatmentcombinationofantivegfinjectionslasercoagulationandcryotherapyonpatientswithtype3coatsdisease
AT guangdadeng effectsofatreatmentcombinationofantivegfinjectionslasercoagulationandcryotherapyonpatientswithtype3coatsdisease
AT jinghualiu effectsofatreatmentcombinationofantivegfinjectionslasercoagulationandcryotherapyonpatientswithtype3coatsdisease
AT yanma effectsofatreatmentcombinationofantivegfinjectionslasercoagulationandcryotherapyonpatientswithtype3coatsdisease
AT hailu effectsofatreatmentcombinationofantivegfinjectionslasercoagulationandcryotherapyonpatientswithtype3coatsdisease
_version_ 1725327161842204672